Baidu
map

2020 ESMO共识建议:癌症患者在肿瘤治疗过程中心脏病的管理

2020-02-01 欧洲肿瘤内科学会 Ann Oncol. 2020 Feb;31(2):171-190.

2020年2月,欧洲肿瘤内科学会(ESMO)发布了癌症患者在肿瘤治疗过程中心脏病的管理共识建议,癌症和心血管疾病是发达国家最普遍的疾病,越来越多的证据表明,这些疾病通过共同的危险因素相互影响。本文主要针对癌症患者在肿瘤治疗过程中心脏病的管理提供共识建议。

中文标题:

2020 ESMO共识建议:癌症患者在肿瘤治疗过程中心脏病的管理

英文标题:

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.

发布机构:

欧洲肿瘤内科学会

发布日期:

2020-02-01

简要介绍:

2020年2月,欧洲肿瘤内科学会(ESMO)发布了癌症患者在肿瘤治疗过程中心脏病的管理共识建议,癌症和心血管疾病是发达国家最普遍的疾病,越来越多的证据表明,这些疾病通过共同的危险因素相互影响。本文主要针对癌症患者在肿瘤治疗过程中心脏病的管理提供共识建议。

 

拓展指南:心脏相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2020 ESMO共识建议:癌症患者在肿瘤治疗过程中心脏病的管理)] GetToolGuiderByIdResponse(projectId=1, id=f65ba1c001863a0c, title=2020 ESMO共识建议:癌症患者在肿瘤治疗过程中心脏病的管理, enTitle=Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations., guiderFrom=Ann Oncol. 2020 Feb;31(2):171-190., authorId=null, author=, summary=2020年2月,欧洲肿瘤内科学会(ESMO)发布了癌症患者在肿瘤治疗过程中心脏病的管理共识建议,癌症和心血管疾病是发达国家最普遍的疾病,越来越多的证据表明,这些疾病通过共同的危险因素相互影响。本文主要针对癌症患者在肿瘤治疗过程中心脏病的管理提供共识建议。 , cover=, journalId=null, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology )是1975年成立的非盈利组织,是欧洲领先的专业组织,致力于提高肿瘤内科的专业性,推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Sat Feb 01 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<P>2020年2月,欧洲肿瘤内科学会(ESMO)发布了癌症患者在肿瘤治疗过程中心脏病的管理共识建议,癌症和心血管疾病是发达国家最普遍的疾病,越来越多的证据表明,这些疾病通过共同的危险因素相互影响。本文主要针对癌症患者在肿瘤治疗过程中心脏病的管理提供共识建议。 </P> <P> </P>拓展指南:<strong>与<font color=red>心脏</font>相关指南:</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=370651c00185e101" title="中国心脏康复与二级预防指南解读" target=_blank>中国心脏康复与二级预防指南解读</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=eb2bd1c0018569cd" title="2019年欧洲加速康复外科协会《心脏手术围术期监护指南》解读" target=_blank>2019年欧洲加速康复外科协会《心脏手术围术期监护指南》解读</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=729231c0018a85cc" title="心脏骤停复苏后血流动力学管理的专家共识" target=_blank>心脏骤停复苏后血流动力学管理的专家共识</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=00a981c0018a266a" title="心脏骤停基层诊疗指南(实践版·2019)" target=_blank>心脏骤停基层诊疗指南(实践版·2019)</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=95c5a1c0018a0220" title="先天性心脏病外科治疗中国专家共识(一):大动脉调转术应用" target=_blank>先天性心脏病外科治疗中国专家共识(一):大动脉调转术应用</a></li> 更多信息请点击:<a href="//m.capotfarm.com/guideline/list.do?q=%E5%BF%83%E8%84%8F" target=_blank>有关心脏更多指南</a></ul>, tagList=[TagDto(tagId=516, tagName=癌症), TagDto(tagId=577, tagName=心脏病)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5281, appHits=108, showAppHits=9, pcHits=1900, showPcHits=4404, likes=23, shares=8, comments=3, approvalStatus=1, publishedTime=Mon Feb 17 21:51:17 CST 2020, publishedTimeString=2020-02-01, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Feb 17 21:51:17 CST 2020, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 17:53:37 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2020 ESMO共识建议:癌症患者在肿瘤治疗过程中心脏病的管理)])
2020 ESMO共识建议:癌症患者在肿瘤治疗过程中心脏病的管理
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1057205, encodeId=c259105e205fe, content=谢谢 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:40:22 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057196, encodeId=debb105e1961d, content=谢谢 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:39:15 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999690, encodeId=e5dd999690df, content=可以, beContent=null, objectType=guider, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210627/96b10214fe8f4a039febb3ea9891a8aa/df59dd3a997242479937a4f3feae3b05.jpg, createdBy=052c5526600, createdName=乌拉小草, createdTime=Thu Jul 15 10:55:15 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2021-10-03 H8888888

    谢谢 学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1057205, encodeId=c259105e205fe, content=谢谢 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:40:22 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057196, encodeId=debb105e1961d, content=谢谢 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:39:15 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999690, encodeId=e5dd999690df, content=可以, beContent=null, objectType=guider, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210627/96b10214fe8f4a039febb3ea9891a8aa/df59dd3a997242479937a4f3feae3b05.jpg, createdBy=052c5526600, createdName=乌拉小草, createdTime=Thu Jul 15 10:55:15 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2021-10-03 H8888888

    谢谢 学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1057205, encodeId=c259105e205fe, content=谢谢 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:40:22 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057196, encodeId=debb105e1961d, content=谢谢 学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 17:39:15 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999690, encodeId=e5dd999690df, content=可以, beContent=null, objectType=guider, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210627/96b10214fe8f4a039febb3ea9891a8aa/df59dd3a997242479937a4f3feae3b05.jpg, createdBy=052c5526600, createdName=乌拉小草, createdTime=Thu Jul 15 10:55:15 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2021-07-15 乌拉小草

    可以

    0

Baidu
map
Baidu
map
Baidu
map